Polycystic ovary syndrome and nonalcoholic fatty liver disease

Georgescu, Carmen Emanuela

doi:10.1016/b978-0-12-823045-9.00007-9

Cited by 4 publications

(1 citation statement)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study showed that the prevalence of NAFLD was significantly higher in women with PCOS than in those without, with a prevalence of 51.56 and 29.64%, respectively ( Falzarano et al, 2022 ). Meanwhile, a study revealed that PCOS was also more prevalent in female NAFLD patients with a prevalence of 50% up to a high of 70%, which is significantly higher than in those without NAFLD ( Georgescu, 2022 ). Furthermore, studies have shown that both PCOS patients and NAFLD patients can increase the risk of cardiovascular disease ( Dokras, 2019 ), and metabolic abnormalities were more pronounced in the PCOS patients with concurring NAFLD ( Sarkar et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome

Chen

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) is the most common metabolic and endocrinopathies disorder in women of reproductive age and non-alcoholic fatty liver (NAFLD) is one of the most common liver diseases worldwide. Previous research has indicated potential associations between PCOS and NAFLD, but the underlying pathophysiology is still not clear. The present study aims to identify the differentially expressed genes (DEGs) between PCOS and NAFLD through the bioinformatics method, and explore the associated molecular mechanisms.Methods: The microarray datasets GSE34526 and GSE63067 were downloaded from Gene Expression Omnibus (GEO) database and analyzed to obtain the DEGs between PCOS and NAFLD with the GEO2R online tool. Next, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the DEGs were performed. Then, the protein-protein interaction (PPI) network was constructed and the hub genes were identified using the STRING database and Cytoscape software. Finally, NetworkAnalyst was used to construct the network between the targeted microRNAs (miRNAs) and the hub genes.Results: A total of 52 genes were identified as DEGs in the above two datasets. GO and KEGG enrichment analysis indicated that DEGs are mostly enriched in immunity and inflammation related pathways. In addition, nine hub genes, including TREM1, S100A9, FPR1, NCF2, FCER1G, CCR1, S100A12, MMP9, and IL1RN were selected from the PPI network by using the cytoHubba and MCODE plug-in. Then, four miRNAs, including miR-20a-5p, miR-129-2-3p, miR-124-3p, and miR-101-3p, were predicted as possibly the key miRNAs through the miRNA-gene network construction.Conclusion: In summary, we firstly constructed a miRNA-gene regulatory network depicting interactions between the predicted miRNA and the hub genes in NAFLD and PCOS, which provides novel insights into the identification of potential biomarkers and valuable therapeutic leads for PCOS and NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome

Chen

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

Cleome arabica L mitigates bisphenol A-induced ovarian dysfunction and inflammation in Wistar rats: biochemical, histopathological, pharmacokinetic, and in silico studies

Allagui,

Sdayria,

Athmouni

et al. 2024

3 Biotech

View full text Add to dashboard Cite

Understanding Pain in Polycystic Ovary Syndrome: Health Risks and Treatment Effectiveness

Cherlin,

Mohammed,

Ottey

et al. 2024

Preprint

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women, often accompanied by various symptoms including significant pain, such as dysmenorrhea, abdominal, and pelvic pain, which remains underexplored. This retrospective study examines electronic health records (EHR) data to assess the prevalence of pain in women with PCOS. Conducted on May 29, 2024, using data from 120 Health Care Organizations within the TriNetX Global Network, the study involved 76,859,666 women from diverse racial backgrounds. The analysis focused on the prevalence of pain among women with PCOS, both overall and in those prescribed PCOS-related medications. Relative risk ratios (RR) were calculated for future health outcomes and stratified by self-reported race. The study found that 19.21% of women with PCOS experienced pain, with the highest prevalence among Black or African American (32.11%) and White (30.75%) populations. Both the PCOS and PCOS and Pain cohorts exhibited increased RR for various health conditions, with significant differences noted across racial groups for infertility, ovarian cysts, obesity, and respiratory diseases. Additionally, women with PCOS who were treated with PCOS-related medications showed a decrease in pain diagnoses following treatment. In conclusion, this study highlights the critical need to address pain in the diagnosis and management of PCOS due to its significant impact on patient health outcomes.

show abstract

Polycystic ovary syndrome and nonalcoholic fatty liver disease

Cited by 4 publications

References 129 publications

Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome

Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome

Cleome arabica L mitigates bisphenol A-induced ovarian dysfunction and inflammation in Wistar rats: biochemical, histopathological, pharmacokinetic, and in silico studies

Understanding Pain in Polycystic Ovary Syndrome: Health Risks and Treatment Effectiveness

Contact Info

Product

Resources

About